JP2025532665A - 腫瘍への抵抗における抗体およびその使用 - Google Patents

腫瘍への抵抗における抗体およびその使用

Info

Publication number
JP2025532665A
JP2025532665A JP2025517108A JP2025517108A JP2025532665A JP 2025532665 A JP2025532665 A JP 2025532665A JP 2025517108 A JP2025517108 A JP 2025517108A JP 2025517108 A JP2025517108 A JP 2025517108A JP 2025532665 A JP2025532665 A JP 2025532665A
Authority
JP
Japan
Prior art keywords
cancer
antigen
antibody
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025517108A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025532665A5 (cg-RX-API-DMAC7.html
Inventor
▲イー▼ 羅
連 ▲ディー▼ 陳
威 鋒 黄
小 牛 繆
堯 ▲イエン▼
超 王
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotheus Inc
Original Assignee
Biotheus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotheus Inc filed Critical Biotheus Inc
Publication of JP2025532665A publication Critical patent/JP2025532665A/ja
Publication of JP2025532665A5 publication Critical patent/JP2025532665A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Hospice & Palliative Care (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2025517108A 2022-09-20 2023-09-19 腫瘍への抵抗における抗体およびその使用 Pending JP2025532665A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202211142594 2022-09-20
CN202211142594.0 2022-09-20
PCT/CN2023/119761 WO2024061223A1 (zh) 2022-09-20 2023-09-19 抗体及其在抗肿瘤中的应用

Publications (2)

Publication Number Publication Date
JP2025532665A true JP2025532665A (ja) 2025-10-01
JP2025532665A5 JP2025532665A5 (cg-RX-API-DMAC7.html) 2026-02-09

Family

ID=90453915

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025517108A Pending JP2025532665A (ja) 2022-09-20 2023-09-19 腫瘍への抵抗における抗体およびその使用

Country Status (5)

Country Link
EP (1) EP4592315A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025532665A (cg-RX-API-DMAC7.html)
KR (1) KR20250075621A (cg-RX-API-DMAC7.html)
CN (1) CN119894933A (cg-RX-API-DMAC7.html)
WO (1) WO2024061223A1 (cg-RX-API-DMAC7.html)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
JP2006500921A (ja) 2002-07-30 2006-01-12 ブリストル−マイヤーズ スクイブ カンパニー ヒト4−1bbに対するヒト化抗体
EP3698807A1 (en) * 2005-01-21 2020-08-26 Genentech, Inc. Fixed dosing of her antibodies
RU2727165C2 (ru) 2015-05-04 2020-07-21 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Слитый полипептид с противораковой активностью
WO2018090950A1 (zh) * 2016-11-18 2018-05-24 北京韩美药品有限公司 抗pd‐1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
AU2020357944A1 (en) 2019-09-30 2022-03-31 Adimab, Llc CH1 domain variants engineered for preferential light chain pairing and multispecific antibodies comprising the same
CN113004415B (zh) * 2019-12-19 2022-09-30 合肥瀚科迈博生物技术有限公司 靶向her2和4-1bb的双特异性抗体及其应用
CN114195894B (zh) * 2020-09-17 2025-02-25 普米斯生物技术(珠海)有限公司 一种靶向4-1bb的抗体及其应用
CN114195900B (zh) * 2020-09-17 2024-02-23 普米斯生物技术(珠海)有限公司 一种抗4-1bb/pd-l1双特异性抗体及其用途
WO2023020537A1 (zh) * 2021-08-18 2023-02-23 普米斯生物技术(珠海)有限公司 一种双特异性抗体及其用途

Also Published As

Publication number Publication date
CN119894933A (zh) 2025-04-25
KR20250075621A (ko) 2025-05-28
EP4592315A1 (en) 2025-07-30
WO2024061223A1 (zh) 2024-03-28

Similar Documents

Publication Publication Date Title
CN110305210B (zh) 新型抗体分子、其制备方法及其用途
KR20220050971A (ko) 신규 항-cd39 항체
JP2022510253A (ja) 抗-4-1bb抗体およびその用途
KR20210100654A (ko) Cd3 항체 및 그의 약제학적 용도
TWI797609B (zh) 抗pd-1和pd-l1的四價雙特異性抗體
WO2017059387A1 (en) Binding molecules with modified j-chain
JP2023540526A (ja) ネクチン-4抗体およびそれの使用
KR20200063153A (ko) Cd137을 표적화하는 항체 및 이의 사용 방법
WO2020168555A1 (zh) Cd3抗原结合片段及其应用
WO2022166940A1 (en) Cldn18.2/cd3 bispecific antibodies for the therapy of cldn18.2-expressing solid tumors
JP2024531462A (ja) Fap/cd40結合分子及びその医薬的使用
KR20230028708A (ko) 항-b7-h4/항-4-1bb 이중특이적 항체 및 이의 용도
JP7352007B2 (ja) ヒト化抗vegfモノクローナル抗体
KR20200063147A (ko) Pdl1 표적화 항체 및 이의 사용 방법
KR20250143344A (ko) 항-cdh6 항체 및 이의 용도
CN114829405B (zh) 抗bcma/抗4-1bb双特异性抗体及其用途
WO2023236991A1 (zh) 靶向her2,pd-l1和vegf的三特异性抗体
WO2025016459A1 (zh) 一种抗fgfr2/pd-1双特异性抗体
US20250326840A1 (en) BISPECIFIC ANTIBODY TARGETING SIRP-alpha AND PD-L1 OR ANTIGEN-BINDING FRAGMENT THEREOF AND USE
WO2023030511A1 (en) Bi-functional fusion protein and uses thereof
WO2023186100A1 (zh) 抗ror1的抗体及其用途
EP4592315A1 (en) Antibody and use thereof in resisting tumor
KR102955501B1 (ko) Cd137을 표적화하는 항체 및 이의 사용 방법
WO2025103456A1 (en) Gprc5d-binding moieties, chimeric antigen receptors and uses thereof
TWI835166B (zh) 靶向pd-1和/或ox40的特異性結合蛋白及其應用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260130